- conflicts or gaps
- [[{"field": {"value": "employees.headcount", "source_urls": ["https://www.ycombinator.com/companies/venostent", "https://www.linkedin.com/company/venostent", "https://tracxn.com/d/companies/venostent/__axZpWP0LdJQZgi-b0Ea8wRqObfkLE8uzbDcEE5MKlzA"]}, "issue": {"value": "Y Combinator lists team size 17; LinkedIn reports ~31 employees; Tracxn reports 33 as of May 2026. YC figure appears stale.", "source_urls": ["https://www.ycombinator.com/companies/venostent", "https://www.linkedin.com/company/venostent", "https://tracxn.com/d/companies/venostent/__axZpWP0LdJQZgi-b0Ea8wRqObfkLE8uzbDcEE5MKlzA"]}}, {"field": {"value": "funding.total_raised_usd", "source_urls": ["https://www.employbl.com/companies/venostent", "https://www.finsmes.com/2021/02/venostent-raises-2-3m-in-seed-funding.html", "https://www.prnewswire.com/news-releases/venostent-completes-20-million-series-a-with-4-million-investment-from-norwest-venture-partners-302183962.html"]}, "issue": {"value": "Sum of disclosed equity rounds is $22.835M ($535K SAFE + $2.3M seed + $20M Series A). Third-party aggregators report ~$29.8M–$30.6M total including grants and undisclosed early rounds; FinSMEs reported >$6M total as of Feb 2021 including non-dilutive NIH/NSF/KidneyX grants.", "source_urls": ["https://www.employbl.com/companies/venostent", "https://www.finsmes.com/2021/02/venostent-raises-2-3m-in-seed-funding.html", "https://www.prnewswire.com/news-releases/venostent-completes-20-million-series-a-with-4-million-investment-from-norwest-venture-partners-302183962.html"]}}, {"field": {"value": "products.SelfWrap.clinical_trial_enrollment", "source_urls": ["https://clinicaltrials.gov/study/NCT06001827", "https://www.venostent.com/patients-and-providers", "https://www.prnewswire.com/news-releases/venostent-completes-20-million-series-a-with-4-million-investment-from-norwest-venture-partners-302183962.html"]}, "issue": {"value": "ClinicalTrials.gov and VenoStent patient page list ~600 participants across up to 30 sites; 2024 press releases and conference materials describe a 200-patient pivotal RCT (~20 sites). Enrollment target may have been expanded or sources reflect different protocol versions.", "source_urls": ["https://clinicaltrials.gov/study/NCT06001827", "https://www.venostent.com/patients-and-providers", "https://www.prnewswire.com/news-releases/venostent-completes-20-million-series-a-with-4-million-investment-from-norwest-venture-partners-302183962.html", "https://www.clinicaltrialsarena.com/news/venostent-raises-20m-in-series-a-to-develop-bioabsorbable-perivascular-wrap/"]}}, {"field": {"value": "identity.market_size_claims", "source_urls": ["https://www.ycombinator.com/companies/venostent", "https://www.venostent.com/company"]}, "issue": {"value": "YC long description cites 10 million dialysis and bypass surgeries per year with half failing; VenoStent company page cites 5 million vascular surgeries per year. Market scope and failure-rate statistics differ across sources.", "source_urls": ["https://www.ycombinator.com/companies/venostent", "https://www.venostent.com/company", "https://www.finsmes.com/2021/02/venostent-raises-2-3m-in-seed-funding.html"]}}, {"field": {"value": "funding.pre_seed_rounds", "source_urls": ["https://www.venostent.com/press/venostent-accepted-into-y-combinator-and-closes-oversubscribed-safe-round"]}, "issue": {"value": "Company press release references first two funding rounds in 2018 and 2019 with Texas HALO Fund and Cowtown Angels, but no public dollar amounts found for those rounds.", "source_urls": ["https://www.venostent.com/press/venostent-accepted-into-y-combinator-and-closes-oversubscribed-safe-round"]}}, {"field": {"value": "identity.display_name", "source_urls": ["https://www.ycombinator.com/companies/venostent", "https://www.venostent.com/press"]}, "issue": {"value": "YC slug is venostent; primary branding is VenoStent; some older press entries use Venostent (lowercase t).", "source_urls": ["https://www.ycombinator.com/companies/venostent", "https://www.venostent.com/press"]}}, {"field": {"value": "exit_status.commercial_availability", "source_urls": ["https://www.venostent.com/company", "https://www.norwest.com/blog/venostent-the-promise-of-safer-treatment-for-dialysis-patients/"]}, "issue": {"value": "SelfWrap is investigational only. Norwest blog (Jun 2024) states FDA approval could follow positive pivotal trial results in 2026, but no FDA clearance or commercial launch date confirmed in primary company filings.", "source_urls": ["https://www.venostent.com/company", "https://www.norwest.com/blog/venostent-the-promise-of-safer-treatment-for-dialysis-patients/", "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/venostent-technology-receives-breakthrough-device-designation-by-fda-701726"]}}]]
- source urls
- ["https://clinicaltrials.gov/study/NCT06001827", "https://tracxn.com/d/companies/venostent/__axZpWP0LdJQZgi-b0Ea8wRqObfkLE8uzbDcEE5MKlzA", "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/venostent-technology-receives-breakthrough-device-designation-by-fda-701726", "https://www.accessnewswire.com/newsroom/en/publishing-and-media/venostent-completes-16m-series-a-financing-receives-ide-approval-from-fda-to-be-771019", "https://www.clinicaltrialsarena.com/news/venostent-raises-20m-in-series-a-to-develop-bioabsorbable-perivascular-wrap/", "https://www.employbl.com/companies/venostent", "https://www.finsmes.com/2021/02/venostent-raises-2-3m-in-seed-funding.html", "https://www.finsmes.com/2023/08/venostent-closes-16m-series-a-financing.html", "https://www.linkedin.com/company/venostent", "https://www.massdevice.com/venostent-raises-20m-bioabsorbable-perivascular-wrap/", "https://www.norwest.com/blog/venostent-the-promise-of-safer-treatment-for-dialysis-patients/", "https://www.prnewswire.com/news-releases/venostent-completes-20-million-series-a-with-4-million-investment-from-norwest-venture-partners-302183962.html", "https://www.venostent.com/", "https://www.venostent.com/company", "https://www.venostent.com/patients-and-providers", "https://www.venostent.com/press", "https://www.venostent.com/press/venostent-accepted-into-y-combinator-and-closes-oversubscribed-safe-round", "https://www.ycombinator.com/companies/venostent", "https://yc-oss.github.io/api/batches/summer-2020/venostent.json"]